Cerebrospinal Fluid Profiles and Their Changes after Intraventricular Chemotherapy as Prognostic or Predictive Markers for Patients with Leptomeningeal Carcinomatosis

다국어 초록 (Multilingual Abstract)

Objective : Here, we evaluated whether cerebrospinal fluid (CSF) profiles and their changes after intraventricular chemotherapy for leptomeningeal carcinomatosis (LMC) could predict the treatment response or be prognostic for patient overall survival (OS) along with clinical factors. Methods : Paired 1) pretreatment lumbar, 2) pretreatment ventricular, and 3) posttreatment ventricular samples and their CSF profiles were collected retrospectively from 148 LMC patients who received Ommaya reservoir installation and intraventricular chemotherapy. CSF profile changes were assessed by calculating the differences between posttreatment and pretreatment samples from the same ventricular compartment. CSF cell counts were further differentiated into total and other based on clinical laboratory reports. Results : For the treatment response, a decreased CSF 'total' cell count tended to be associated with a 'controlled' increase in intracranial pressure (ICP) (p=0.059), but other profile changes were not associated with either the control of increased ICP or the cytology response. Among the pretreatment CSF profiles, lumbar protein level and ventricular cell count were significantly correlated with OS in univariable analysis, but they were not significant in multi-variable analysis. Among CSF profile changes, a decrease in 'other' cell count showed worse OS than 'no change' or increased groups (p=0.001). The cytological response was significant for OS, but the hazard ratio of partial remission was paradoxically higher than that of 'no response'. Conclusion : A decrease in other cell count of CSF after intraventricular chemotherapy was associated with poor OS in LMC patients. We suggest that more specific CSF biomarkers of cancer cell origin are needed.

참고문헌 (Reference)

1 Gwak HS, "Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis : a phase II study" 19 : 1044-1045, 2014

2 Wen PY, "Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group" 28 : 1963-1972, 2010

3 Yap HY, "Treatment for meningeal carcinomatosis in breast cancer" 50 : 219-222, 1982

4 Boogerd W, "The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer : a randomised study" 40 : 2726-2733, 2004

5 Gauthier H, "Survival of breast cancer patients with meningeal carcinomatosis" 21 : 2183-2187, 2010

6 Twijnstra A, "Serial lumbar and ventricle cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumours" 50 : 313-320, 1987

7 Ahn JH, "Risk for leptomeningeal seeding after resection for brain metastases : implication of tumor location with mode of resection" 116 : 984-993, 2012

8 Youngbo Shim, "Retrospective Analysis of Cerebrospinal Fluid Profiles in 228 Patients with Leptomeningeal Carcinomatosis : Differences According to the Sampling Site, Symptoms, and Systemic Factors" 대한신경외과학회 59 (59): 570-576, 2016

9 Lin NU, "Response assessment criteria for brain metastases: proposal from the RANO group" 16 : e270-e278, 2015

10 Chamberlain MC, "Radioisotope CSF flow studies in leptomeningeal metastases" 38 : 135-140, 1998

11 Harstad L, "Prognostic factors and outcomes in patients with leptomeningeal melanomatosis" 10 : 1010-1018, 2008

12 Waki F, "Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors" 93 : 205-212, 2009

13 Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada" 92 : 205-216, 2000

14 Freilich RJ, "Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis" 38 : 51-57, 1995

15 Gleissner B, "Neoplastic meningitis" 5 : 443-452, 2006

16 Teplyuk NM, "MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity" 14 : 689-700, 2012

17 Fizazi K, "Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen" 77 : 1315-1323, 1996

18 Boogerd W, "Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment" 67 : 1685-1695, 1991

19 de Azevedo CR, "Meningeal carcinomatosis in breast cancer : prognostic factors and outcome" 104 : 565-572, 2011

20 Clamon G, "Meningeal carcinomatosis from breast cancer : spinal cord vs. brain involvement" 9 : 213-217, 1987

21 Nakagawa H, "Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumors" 12 : 111-120, 1992

22 Glass JP, "Malignant cells in cerebrospinal fluid(CSF) : the meaning of a positive CSF cytology" 29 : 1369-1375, 1979

23 Singh SK, "MR imaging of leptomeningeal metastases : comparison of three sequences" 23 : 817-821, 2002

24 Morris PG, "Leptomeningeal metastasis from non-small cell lung cancer : survival and the impact of whole brain radiotherapy" 7 : 382-385, 2012

25 Herrlinger U, "Leptomeningeal metastasis : survival and prognostic factors in 155 patients" 223 : 167-178, 2004

26 Chamberlain MC, "Leptomeningeal metastasis" 22 : 627-635, 2010

27 Taillibert S, "Leptomeningeal metastases from solid malignancy : a review" 75 : 85-99, 2005

28 Yousem DM, "Leptomeningeal metastases : MR evaluation" 14 : 255-261, 1990

29 Balm M, "Leptomeningeal carcinomatosis. Presenting features and prognostic factors" 53 : 626-632, 1996

30 Bruna J, "Leptomeningeal carcinomatosis : prognostic implications of clinical and cerebrospinal fluid features" 115 : 381-389, 2009

31 Grossman SA, "Leptomeningeal carcinomatosis" 25 : 103-119, 1999

32 Singh SK, "Intracranial leptomeningeal metastases : comparison of depiction at FLAIR and contrast-enhanced MR imaging" 217 : 50-53, 2000

33 Chamberlain MC, "Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment" 36 (36): S35-S45, 2009

34 Glantz MJ, "Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status" 75 : 2919-2931, 1995

35 Wasserstrom WR, "Diagnosis and treatment of leptomeningeal metastases from solid tumors : experience with 90 patients" 49 : 759-772, 1982

36 Lee JS, "Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer" 154 : 339-349, 2015

37 Tu Q, "CellSearch technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis" 90 : 352-357, 2015

38 Jayson GC, "Carcinomatous meningitis in solid tumours" 7 : 773-786, 1996

39 Chamberlain MC, "Carcinoma meningitis secondary to nonsmall cell lung cancer : combined modality therapy" 55 : 506-512, 1998

40 Hyun JW, "CYFRA 21-1 levels in cerebrospinal fluid as a putative therapeutic monitoring biomarker for patients with leptomeningeal carcinomatosis : a pilot study" 28 : 81-89, 2020

41 Gwak HS, "Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer" 8 : 599-605, 2013

42 An YJ, "An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients" 136 : 162-171, 2015

43 Hitchins RN, "A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis" 5 : 1655-1662, 1987

44 Groves MD, "A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies" 10 : 208-215, 2008

45 Chamberlain MC, "A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases" 3 : 42-45, 2001